Article
ARID1B alterations identify aggressive tumors in neuroblastoma.
Oncotarget - 11 Jul 2017
Lee Soo Hyun, Kim Jung-Sun, Zheng Siyuan, Huse Jason T, Bae Joon Seol, Lee Ji Won, Yoo Keon Hee, Koo Hong Hoe, Kyung Sungkyu, Park Woong-Yang, Sung Ki W
Abstract excerpt
Targeted panel sequencing was performed to determine molecular targets and biomarkers in 72 children with neuroblastoma. Frequent genetic alterations were detected in ALK (16.7%), BRCA1 (13.9%), ATM (12.5%), and PTCH1 (11.1%) in an 83-gene panel. Molecular targets for targeted therapy were identified in 16 of 72 patients (22.2%). Two-thirds of ALK mutations were known to increase sensitivity to ALK inhibitors....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.